BioWorld

May 21, 2004

Pharmion Gets 'Full Approval' For Vidaza In MDS Subtypes

Pharmion Corp.'s value soared 47.8 percent Thursday after the FDA issued full approval of Vidaza, the firm's orphan drug for myelodysplastic syndromes (MDS). (BioWorld Today) Read More

Biomira Spins Out Company To Put L-IL-2 Back In Clinic

ZymoGenetics Out-Licenses Target To Amgen For $10M

Molecular Insight $7M Series B To Advance Lead Imaging Agent

Boston Life Sciences Begins Phase III Study Of Altropane

Digestive Disease Week

Other News To Note

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...